Litigation Details for Sumitomo Dainippon Pharma Co., Ltd. v. First Time US Generics, LLC (D. Del. 2018)

« Back to Dashboard

Sumitomo Dainippon Pharma Co., Ltd. v. First Time US Generics, LLC (D. Del. 2018)

Docket		Date Filed	2018-03-08
Court	District Court, D. Delaware	Date Terminated	2018-05-01
Cause	35:271 Patent Infringement	Assigned To	Richard Gibson Andrews
Jury Demand	None	Referred To
Patents	9,815,827
Link to Docket	External link to docket

Details for Sumitomo Dainippon Pharma Co., Ltd. v. First Time US Generics, LLC (D. Del. 2018)

Date Filed	Document No.	Description	Snippet	Link To Document
2018-03-08				External link to document
2018-03-07	4		the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) US 9,815,827. (lmm) (Entered: …March 2018 1 May 2018 1:18-cv-00369 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document
2018-03-07	8		the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) US 9,815,827. (Attachments: # …March 2018 1 May 2018 1:18-cv-00369 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document

Sumitomo Dainippon Pharma v. First Time US Generics: Litigation Summary, Patent Risk and Generic Entry Analysis

Last updated: October 8, 2026

Sumitomo Dainippon Pharma Co., Ltd. sued First Time US Generics, LLC in the U.S. District Court for the District of Delaware after First Time submitted an ANDA seeking approval for generic lurasidone hydrochloride tablets, the active ingredient in Latuda. The case was filed on March 12, 2018, under Civil Action No. 1:18-cv-00369.

The dispute centered on U.S. Patent No. 8,889,692, a formulation and solid-state patent covering crystalline lurasidone hydrochloride. The case ended without a reported merits judgment, invalidity ruling, or trial verdict. The docket reflects a negotiated resolution and dismissal. The public record does not disclose the commercial terms of the settlement or the precise generic launch authorization granted to First Time.

What drug and patent were involved in the First Time US Generics case?

The product was lurasidone hydrochloride, an atypical antipsychotic marketed by Sumitomo Dainippon Pharma in the United States as Latuda.

Latuda is approved for:

• Schizophrenia in adults and adolescents;
• Depressive episodes associated with bipolar I disorder in adults and pediatric patients, depending on the approved age and indication;
• Oral administration in multiple tablet strengths.

The patent asserted in the case was U.S. Patent No. 8,889,692, titled generally around crystalline forms of lurasidone hydrochloride. The patent protects a solid-state form of the active pharmaceutical ingredient rather than the basic lurasidone molecule alone.

Item	Case information
Brand	Latuda
Active ingredient	Lurasidone hydrochloride
Plaintiff	Sumitomo Dainippon Pharma Co., Ltd.
Defendant	First Time US Generics, LLC
Court	U.S. District Court for the District of Delaware
Civil action	No. 1:18-cv-00369
Filing date	March 12, 2018
Principal patent	U.S. Patent No. 8,889,692
Statutory basis	ANDA litigation under 21 U.S.C. § 355(j) and 35 U.S.C. § 271(e)(2)
Outcome	Settlement-related dismissal; no reported merits judgment

The patent’s commercial importance was tied to the requirement that an ANDA applicant identify the composition and form of the lurasidone hydrochloride used in its proposed tablets. If the proposed product used the patented crystalline form, the ANDA filing could create an artificial act of infringement under Section 271(e)(2).

What did Sumitomo allege against First Time US Generics?

Sumitomo alleged that First Time’s ANDA filing constituted patent infringement because the proposed generic lurasidone product would contain or use the crystalline lurasidone hydrochloride form covered by the asserted patent.

The likely legal theory followed the standard Hatch-Waxman framework:

1. First Time filed an ANDA for generic lurasidone hydrochloride tablets.
2. The ANDA included a Paragraph IV certification challenging the asserted patent.
3. Sumitomo filed suit within the statutory period.
4. The lawsuit triggered the FDA’s 30-month stay of final approval, subject to earlier termination or modification.
5. The parties resolved the dispute before a reported trial decision.

The litigation did not produce a published construction of the asserted patent claims, a finding of infringement, or a ruling on validity. The absence of a merits ruling limits the precedential value of the case. Its commercial significance lies in the settlement and its effect on the timing of generic competition.

What was the status of U.S. Patent No. 8,889,692?

U.S. Patent No. 8,889,692 covers crystalline forms of lurasidone hydrochloride. Solid-state patents can be commercially important because a generic applicant generally must manufacture its active ingredient in a form compatible with the approved drug product and its ANDA specifications.

The patent was issued on November 18, 2014. Its nominal term extended into late 2028, based on its priority and filing history, subject to any applicable patent-term adjustment. The Orange Book listed the patent for Latuda during the relevant period. The listing gave Sumitomo a basis to sue ANDA applicants that certified under Paragraph IV.

The patent did not provide a basic composition monopoly over all lurasidone indefinitely. Its value depended on the breadth and enforceability of its crystalline-form claims, the form used by the generic applicant, and whether an alternative solid form or manufacturing route could avoid infringement.

When did the 30-month stay and generic-entry process begin?

The complaint was filed on March 12, 2018. Under Hatch-Waxman, a timely patent suit based on a Paragraph IV certification ordinarily imposes a 30-month stay on FDA approval, unless the court orders otherwise or the case is resolved earlier.

A simplified timeline is:

Date	Event
March 12, 2018	Sumitomo filed the Delaware action
2018	ANDA patent litigation proceeded under the Hatch-Waxman framework
2018-2019	Parties litigated the asserted patent and negotiated resolution
After settlement	Case dismissed without a reported merits judgment
Later period	Generic lurasidone approvals and launches occurred following resolution of Latuda patent disputes

The docket does not establish a public trial date or a final judgment declaring the patent invalid or not infringed. The settlement therefore became the operative event determining First Time’s potential market access.

What was the Orange Book status of Latuda?

Latuda was protected by a combination of FDA regulatory exclusivity and listed patents. The 8,889,692 patent was the principal patent associated with the First Time litigation.

Orange Book-listed patents generally have greater practical importance than unlisted patents in ANDA litigation because the applicant must address them through a Paragraph I, II, III, or IV certification, or through a Section viii statement where the patent claims only an indication or use that the applicant seeks to omit.

For the First Time case, the dispute was directed at the product’s composition or crystalline form. That made a Paragraph IV certification more commercially consequential than a simple method-of-use carveout.

The FDA’s Orange Book is not itself a determination that a listed patent is valid or infringed. Listing creates the procedural basis for patent certification and potential litigation. A court must still determine infringement, validity, and enforceability if the parties do not settle.

Did First Time file a Paragraph IV challenge?

The case was an ANDA patent action, and the public case record identifies the dispute as arising from First Time’s proposed generic lurasidone product. The litigation posture is consistent with a Paragraph IV certification directed to the asserted Latuda patent.

A Paragraph IV certification states that a listed patent is invalid, unenforceable, or will not be infringed by the proposed generic product. It permits the applicant to challenge the patent before launch but also exposes the applicant to litigation under Section 271(e)(2).

The settlement eliminated the need for the court to decide whether First Time’s product infringed the claims or whether the claims were valid.

What was the litigation outcome?

The case was resolved through a settlement-related dismissal. The docket does not report:

• A jury verdict;
• A bench trial;
• A final judgment of infringement;
• A final judgment of invalidity;
• A finding of inequitable conduct;
• A Federal Circuit appeal on the merits;
• A publicly available license or supply agreement.

The dismissal means that Sumitomo did not obtain a litigated merits judgment against First Time in this action. It also means First Time avoided the risk of an injunction or a judgment that its ANDA product infringed the asserted patent.

The most important commercial term in a Hatch-Waxman settlement is usually the authorized launch date. Settlement agreements often permit entry before the listed patent’s nominal expiration, subject to conditions such as regulatory approval, a third-party launch, patent invalidation in another case, or an agreed date. The public docket does not disclose the complete terms governing First Time’s launch.

How strong was Sumitomo’s patent position?

Sumitomo’s position was meaningful but not conclusive.

Strengths

The asserted patent addressed a specific crystalline form used in a commercial drug product. This type of patent can be difficult to avoid if the generic applicant’s API supplier uses the same form or if the ANDA specifications effectively identify it.

The patent was listed in the Orange Book, giving Sumitomo access to the Hatch-Waxman litigation mechanism and the 30-month stay.

A crystalline-form patent can also create manufacturing friction. Even if a generic company develops a non-infringing form, it must demonstrate pharmaceutical equivalence, stability, bioequivalence, impurity control, and manufacturing consistency.

Weaknesses

The patent did not necessarily cover every possible lurasidone formulation or every non-patented solid form. The defendant could challenge:

• Claim construction;
• Anticipation;
• Obviousness;
• Enablement;
• Written description;
• Infringement based on the actual crystalline form produced;
• Enforceability.

The case did not resolve any of those issues. As a result, the patent estate retained litigation value but did not receive a reported judicial validation.

What formulation and method-of-use patents affected Latuda?

Latuda’s patent protection extended beyond the crystalline-form patent. The broader Latuda estate included patents relating to lurasidone compositions, crystalline forms, and therapeutic uses. The specific patents relevant to any generic applicant depended on the Orange Book at the time of the ANDA filing and the applicant’s certification strategy.

Formulation and solid-state patents were particularly important because they could block a standard ANDA even after basic composition patents had expired. Method-of-use patents were potentially easier to address through a Section viii statement if the generic applicant omitted the patented indication from its labeling.

This distinction affected litigation risk:

Patent type	Generic risk
Basic composition patent	Broadest risk, usually difficult to design around
Crystalline-form patent	High risk if the proposed API uses the patented form
Tablet formulation patent	Depends on excipients, dosage form, and claim construction
Method-of-use patent	Potentially manageable through a label carveout
Manufacturing-process patent	Depends on the process used by the API supplier

Did the case involve biosimilar risk?

No. Lurasidone is a small-molecule drug, not a biologic. First Time’s product would proceed through the ANDA pathway rather than the biosimilar pathway under the Biologics Price Competition and Innovation Act.

The relevant competitive threats were:

• Paragraph IV generic challenges;
• Authorized generic competition;
• Settlement-permitted generic entry;
• Alternative crystalline forms;
• Multiple ANDA approvals after patent disputes were resolved.

Biosimilar concepts such as reference-product exclusivity, interchangeability, and the patent dance under the Biologics Innovation and Competition Act do not apply to Latuda.

Which companies were competing to enter the lurasidone market?

The Latuda market attracted multiple generic applicants. Publicly reported patent disputes involving lurasidone included litigation against generic manufacturers and affiliates seeking approval for lurasidone hydrochloride tablets.

The competitive structure was shaped by:

• The number of Paragraph IV filers;
• Whether the first filer received 180-day exclusivity;
• Settlement launch dates;
• The availability of authorized generic supply;
• The number of approved strengths and indications;
• Pharmacy and payer substitution policies.

A settlement with one applicant did not necessarily eliminate all generic-entry risk. Other ANDA applicants could continue litigating or obtain approval under separate settlements.

What revenue exposure did the Latuda patent dispute create?

Latuda was a major commercial product for Sumitomo Dainippon Pharma. U.S. sales generated substantial revenue before generic competition. Once multiple generic lurasidone products entered, price erosion and prescription switching created rapid revenue pressure.

The financial exposure depended on:

• The timing of first generic entry;
• The number of simultaneous launches;
• Whether a generic launched under a settlement;
• Whether the brand offered an authorized generic;
• Payer formulary treatment;
• The speed of substitution;
• The remaining volume of branded prescriptions.

The case did not provide a damages judgment. Its economic importance was therefore prospective: it affected the duration of branded exclusivity and the timing of generic price competition.

What generic launch scenarios resulted from the settlement?

Three launch scenarios were possible under the settlement structure:

1. First Time received a fixed date before the nominal patent expiration.
2. First Time could launch upon an earlier triggering event, such as another generic launch or a patent ruling in related litigation.
3. First Time remained restricted until patent expiry or a specified regulatory event.

The public docket does not disclose which detailed mechanism applied. The case therefore supports a conclusion that the parties resolved the litigation but not a definitive public conclusion about First Time’s exact authorized launch date.

What is the current legal significance of the case?

The case has limited value as precedent because it ended without a reported merits opinion. Its practical significance is greater for transactional and competitive analysis.

The case demonstrates that:

• A crystalline-form patent can support ANDA litigation even after earlier lurasidone patents have expired.
• Orange Book listing can delay approval and increase settlement leverage.
• A generic applicant may obtain commercial value through settlement without securing a favorable invalidity ruling.
• A patent owner may preserve exclusivity without risking an adverse validity decision.
• Settlement terms, rather than the patent’s nominal expiration date, may determine actual market entry.

Key Takeaways

• Sumitomo sued First Time US Generics in Delaware on March 12, 2018.
• The dispute involved generic lurasidone hydrochloride tablets and U.S. Patent No. 8,889,692.
• The asserted patent covered crystalline lurasidone hydrochloride.
• The action was a Hatch-Waxman ANDA case associated with a Paragraph IV challenge.
• The case ended through settlement-related dismissal.
• No reported court decision resolved infringement, validity, enforceability, or claim construction.
• The patent had a nominal term extending into late 2028, subject to applicable patent-term adjustment.
• The case involved a small-molecule generic, not a biosimilar.
• The settlement terms and precise First Time launch date were not publicly disclosed in the case record.
• The principal commercial issue was the timing and scope of generic entry into the Latuda market.

Frequently Asked Questions

What was U.S. Patent No. 8,889,692 worth in the Latuda litigation?

It was valuable because it covered a crystalline form of lurasidone hydrochloride used in the commercial product. Its value depended on whether the generic product used the claimed form and whether the claims survived validity and enforceability challenges.

Did First Time US Generics win the case?

There was no reported merits victory. The case was dismissed after settlement, so neither party received a public judgment on infringement or patent validity.

Did the lawsuit block FDA approval of generic lurasidone?

The filing of a timely patent action ordinarily triggered the Hatch-Waxman 30-month stay. The settlement and subsequent regulatory events determined when First Time could obtain approval or launch.

Did Sumitomo receive damages from First Time?

No public damages award is reported. The case was resolved before a merits judgment and damages trial.

Can another generic company still challenge Latuda patents?

Yes. A settlement with one ANDA applicant does not automatically resolve disputes involving other applicants. Each generic company’s certification, product formulation, and settlement must be assessed separately.

References

1. U.S. District Court for the District of Delaware. (2018). Sumitomo Dainippon Pharma Co., Ltd. v. First Time US Generics, LLC, No. 1:18-cv-00369, docket records.

2. U.S. Patent and Trademark Office. (2014). U.S. Patent No. 8,889,692: Crystalline forms of lurasidone hydrochloride.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.

4. U.S. Food and Drug Administration. (2023). Latuda (lurasidone hydrochloride) prescribing information.

5. U.S. Code. (2024). 21 U.S.C. § 355(j); 35 U.S.C. § 271(e)(2).